{
  "id": 5278431,
  "title": "Earnings call transcript: Aspen Pharmacare lifts FY 2026 profit, guides for stronger 2027",
  "url": "https://urgent.news/2026/09/03/earnings-call-transcript-aspen-pharmacare-lifts-fy-2026-profit-guides",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T07:45:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-aspen-pharmacare-lifts-fy-2026-profit-guides-for-stronger-2027-93CH-4887108"
  },
  "original_language": "en",
  "account": "Aspen Pharmacare reported a 28% increase in full-year normalized headline earnings per share to 802 cents in FY 2026. Normalized EBITDA also rose 14% to 7.7 billion rand, aided by stronger margins, reduced costs, and a significant recovery in cash flow. Free cash flow surged to 3.8 billion rand, up from just 166 million rand a year earlier.\n\nThe company's commercial pharma segment delivered a 5% revenue increase in constant currency terms, or 7% excluding China discontinuations, with EBITDA growing 13% to 5.9 billion rand. Manufacturing experienced a 10% revenue decline due to the loss of a 1 billion rand mRNA contract, but EBITDA still grew 21% to 828 million rand, thanks to cost cuts and efficiency improvements.\n\nAspen benefited from a major balance-sheet reset after divesting its APAC operations, which generated 28 billion rand in gross proceeds. The company is now debt-free, with a net cash position of 800 million rand at year-end.\n\nManagement expects FY 2027 EBITDA to reach at least 9 billion rand, with normalized headline earnings per share growth exceeding 50%. Commercial pharma is projected to grow mid-single-digit in both revenue and EBITDA, while manufacturing is expected to see more than 50% revenue growth, driven by the return of positive EBITDA and revenue surpassing pre-contract levels. Growth drivers include strong sales of Mounjaro in South Africa, the rollout of generic semaglutide, WHO pre-qualification for pediatric vaccines, and an FDA approval for a triple-dose ARV manufacturing process.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 5,
    "also_reported_by": [
      {
        "outlet": "CNA - Business",
        "title": "Snowflake lifts annual product revenue forecast on demand for cloud data platform",
        "url": "https://urgent.news/2026/09/02/snowflake-lifts-annual-product-revenue-forecast-on-demand-for-cloud",
        "published": "2026-09-02T20:11:08.000Z"
      },
      {
        "outlet": "Techmeme",
        "title": "Snowflake reports Q2 revenue up 35% YoY to $1.55B, vs. $1.48B est., and forecasts Q3 and FY 2027 product revenue above estimates; SNOW jumps 22%+ after hours (MarketWatch)",
        "url": "https://urgent.news/2026/09/02/snowflake-reports-q2-revenue-up-35-yoy-to-1-55b-vs-1-48b-est-and",
        "published": "2026-09-02T20:30:26.000Z"
      },
      {
        "outlet": "Techmeme",
        "title": "HPE reports Q3 revenue up 34% YoY to $12.2B, vs. $11.9B est., forecasts FY 2026 and FY 2027 sales growth above est., signs a $3.5B server deal with a cloud firm (Dina Bass/Bloomberg)",
        "url": "https://urgent.news/2026/09/02/hpe-reports-q3-revenue-up-34-yoy-to-12-2b-vs-11-9b-est-forecasts-fy",
        "published": "2026-09-02T21:05:02.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "Earnings call transcript: Snowflake beats Q2 2026 estimates, shares jump 22%",
        "url": "https://urgent.news/2026/09/02/earnings-call-transcript-snowflake-beats-q2-2026-estimates-shares",
        "published": "2026-09-02T22:17:29.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}